Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept/rinucumab - Regeneron Pharmaceuticals

Next Previous
Search
Drug Profile

Aflibercept/rinucumab - Regeneron Pharmaceuticals

Alternative Names: Aflibercept/REGN 2176; Eylea/REGN-2176; Eylea/rinucumab; PDGFR-beta-Eylea combination therapy - Bayer/Regeneron; REGN-2176-3; REGN-2176/aflibercept; REGN-2176/Eylea; Rinucumab/aflibercept; Rinucumab/Eylea

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Wet age-related macular degeneration

Most Recent Events

  • 16 Feb 2017 Regeneron Pharmaceuticals terminates a phase II trial in Wet age related macular degeneration (In Adults, In the elderly) in USA and Japan (NCT02418754)
  • 01 Dec 2016 Discontinued - Phase-II for Wet age-related macular degeneration (In the elderly, In adults) in USA, Japan (Intravitreous)
  • 30 Sep 2016 Top-line efficacy and safety data from a phase II trial in Wet age-related macular degeneration released by Regeneron Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top